

Directing Drugs to Bugs: Antibiotic-Carbohydrate Conjugates targeting Biofilm-associated Lectins of *Pseudomonas aeruginosa*

Joscha Meiers¹⁻³, Eva Zahorska¹⁻³, Teresa Röhrig⁴, Dirk Hauck^{1,2}, Stefanie Wagner^{1,2}, Alexander Titz¹⁻³

¹ Chemical Biology of Carbohydrates (CBCH), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany

² Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, D-38124 Braunschweig, Germany


³ Department of Pharmacy and Department of Chemistry, Saarland University, D-66123 Saarbrücken, Germany

⁴ Drug Design and Optimization (DDOP), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, D-66123 Saarbrücken, Germany


Table of contents



¹ H and ¹³ C-NMR spectra of new compounds	S2 - S24
Gyrase supercoiling inhibition assay gels (Figure S1)	S25
<i>P. aeruginosa</i> PAO1 Biofilm accumulation raw data (Figure S2)	S26 - S27
Lectin inhibition, calculated as K_i [μ M] from IC_{50} (Table S1)	S27
Antibiotic susceptibility assay data in molar concentration (Table S2)	S28
Key compounds and intermediates as SMILES (Table S3)	S29
Purity of key compounds by HPLC-UV (Figure S3)	S30 - S31
Retention times and a representative chromatogram of conjugates and ciprofloxacin from slow gradient HPLC runs for lipophilicity comparison (Table S4, Figure S4)	S32 - S34
SI References	S34

JOM-047_seccol_118-30.10.1.1r




JOM-047_crude.23.1.1r










JOM-061_RPMLC-17-14.10.1.1r











JOM-061_RPMLC-17-14.12.1.1r





























































ZAA-014_DMSO_carbon_40.f1

169.09
168.84
168.46
168.17

149.42

135.15



115.20
114.07



86.07

73.25
71.20
67.92
67.24



61.86





20.63
20.51
20.40
20.36










JOM-046_t25-23.13.1.1r







JOM-060_120-25.10.1.1r



JOM-060_120-25.20.1.1r









Figure S1: representative Gels for each compound in gyrase-catalyzed DNA supercoiling inhibition assays.





22





30



20



23



3





Figure S2: *P. aeruginosa* PAO1 biofilm accumulation raw data.






Table S1: Lectin inhibition, calculated as K_i [μM] from IC_{50} according to Huang et al. [1]. N.a. = not applicable. Data is comparable to experimental K_i -values, determined by ITC. [2]

LecA					LecB _{PAO1}				
compound	n	m	$K_i \pm \text{s.d.}$ [μM]	$\text{IC}_{50} \pm \text{s.d.}$ [μM]	compound	m	$K_i \pm \text{s.d.}$ [μM]	$\text{IC}_{50} \pm \text{s.d.}$ [μM]	
11	1	LecA-probes	4.16 ± 2.99	31.7 ± 11	19	LecB-probe	1.52 ± 0.72	3.91 ± 1.6	
12	2		3.96 ± 2.33	30.9 ± 8.7	30	0	0.82 ± 0.55	2.37 ± 1.2	
13	3		4.01 ± 2.22	31.1 ± 8.3	31	1	0.89 ± 0.39	2.53 ± 0.87	
14	4		3.67 ± 2.54	29.9 ± 9.5	Me-α-D-Man		75.11 ± 9.79	166 ± 22	
22	1		0	3.82 ± 2.13	30.4 ± 8.0	L-Fuc	controls	0.93 ± 0.78	2.63 ± 1.7
23	1		1	1.48 ± 1.47	21.6 ± 5.5	Me-α-L-Fuc		n.a.	0.534 ± 0.07
24	2		0	4.29 ± 0.87	32.2 ± 3.3	LecB _{PA14}			
25	2		1	3.19 ± 0.48	28.0 ± 1.8	19	LecB-probe	0.36 ± 0.04	1.87 ± 0.21
26	3		0	3.00 ± 1.08	27.3 ± 4.0	30	0	0.18 ± 0.01	2.24 ± 0.23
27	3		1	3.53 ± 0.99	29.3 ± 3.7	31	1	0.44 ± 0.05	1.00 ± 0.06
28	4	0	3.27 ± 2.17	28.3 ± 8.1	Me-α-D-Man		21.21 ± 2.08	101 ± 10	
29	4	1	2.70 ± 0.64	26.2 ± 2.4	L-Fuc	controls	0.49 ± 0.07	2.46 ± 0.33	
Me-α-D-Gal			9.76 ± 3.53	71.7 ± 16	Me-α-L-Fuc		0.14 ± 0.02	0.79 ± 0.11	
pNP-β-D-Gal		controls	14.8 ± 4.25	52.7 ± 13					

Table S2: Antibiotic susceptibility assay data in molar concentration [μ M].











compound	target: LecA											target: LecB			references	
	22	23	24	25	26	27	28	29	30	31	20	3	20	3		
molecular mass [g/mol]	739.8	753.8	753.8	767.8	767.8	781.9	781.9	795.9	761.8	775.9	369.4	331.3				
linker length n/m	1/0	1/1	2/0	2/1	3/0	3/1	4/0	4/1	-/0	-/1	0	-				
test organism	MIC [μM]															
<i>E. coli</i> K12 MG1655	2.7	11 - 21	2.7	21	1.3 - 2.6	20	2.6 - 5.11	20	11 - 21	21	n.d.	<0.37				
<i>E. coli</i> DSM 1116	2.7 - 5.4	22	2.7 - 5.3	42	2.6 - 42	5.1 - 41	5.11 - 41	5 - 40	21 - 42	41	n.d.	<0.37				
<i>S. carnosus</i> ^(a)	43	85	42	>83	21	82	10	\geq 80	>84	>82	n.d.	<0.37				
<i>P. aeruginosa</i> PA14 wt	22	\geq 85	11 - 21	>83	10 - 21	>82	41	>80	84	>82	5.4 - 10.8	0.075 - 0.3				
<i>P. aeruginosa</i> PA14 wt + 1 μ g/mL PMBN	5.4 - 22	21 - 85	11 - 21	42 - 83	5.2	41 - 82	2.6 - 10	40 - 80	84	82	0.068 - 1.4	0.075				
<i>P. aeruginosa</i> PA14 Δ lecA	22 - 44	\geq 85	11 - 21	>83	10 - 21	>82	41	>80	\geq 84	>82	11 - 22	0.15-0.24				
<i>P. aeruginosa</i> PA14 Δ lecB	22 - 44	\geq 85	11 - 42	>83	10 - 21	>82	41 - 82	>80	84	>82	11	0.15-0.24				
<i>P. aeruginosa</i> PAO1 wt	22 - 44	>85	21	>83	21 - 42	>82	41 - 82	>80	\geq 84	>82	11 - 22	0.075 - 0.24				
<i>P. aeruginosa</i> PAO1 wt + 1 μ g/mL PMBN	5.4 - 11	42 - 85	5.3 - 11	42 - 83	5.2 - 10	41 - 82	10 - 20	40 - 80	42 - 84	\geq 82	2.7 - 5.4	0.075-0.15				

n.d. = not determined, ^(a) DSM 20501

compound	SMILE	IC ₅₀ LecA ± s.d. [μM]	IC ₅₀ LecB _{PAO1} ± s.d. [μM]	IC ₅₀ LecB _{PA14} ± s.d. [μM]
11	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CN=[N+]=[N-])=O)C=C2)[C@@H]1O</chem>	31.7 ± 11	n.a.	n.a.
12	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCN=[N+]=[N-])=O)C=C2)[C@@H]1O</chem>	30.9 ± 8.7	n.a.	n.a.
13	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCCN=[N+]=[N-])=O)C=C2)[C@@H]1O</chem>	31.1 ± 8.3	n.a.	n.a.
14	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCCCN=[N+]=[N-])=O)C=C2)[C@@H]1O</chem>	29.9 ± 9.5	n.a.	n.a.
19	<chem>C[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CNS(C2=CC=C(CCN=[N+]=[N-])S2)(=O)=O)O1</chem>	n.a.	3.91 ± 1.6	1.87 ± 0.21
20	<chem>O=C(O)C1=CN(C2=CC(N3CCN(CCC#C)CC3)=C(F)C=C2C1=O)C4CC4</chem>	n.a.	n.a.	n.a.
21	<chem>O=C(O)C1=CN(C2=CC(N3CCN(CCC#C)CC3)=C(F)C=C2C1=O)C4CC4</chem>	n.a.	n.a.	n.a.
22	<chem>O=C(O)C1=CN(C2=CC(N3CCN(CC4=CN(CC(NC(C=C5)=CC=C5S[C@H]6[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O6)=O)N=N4)CC3)=C(F)C=C2C1=O)C7CC7</chem>	30.4 ± 8.0	n.a.	n.a.
23	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CN3N=NC(CCN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)=O)C=C2)[C@@H]1O</chem>	21.6 ± 5.5	n.a.	n.a.
24	<chem>O=C(O)C1=CN(C2=CC(N3CCN(CC4=CN(CCC(NC(C=C5)=CC=C5S[C@H]6[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O6)=O)N=N4)CC3)=C(F)C=C2C1=O)C7CC7</chem>	32.2 ± 3.3	n.a.	n.a.
25	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCN3N=NC(CCN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)=O)C=C2)[C@@H]1O</chem>	28.0 ± 1.8	n.a.	n.a.
26	<chem>O=C(O)C1=CN(C2=CC(N3CCN(CC4=CN(CCCC(NC(C=C5)=CC=C5S[C@H]6[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O6)=O)N=N4)CC3)=C(F)C=C2C1=O)C7CC7</chem>	27.3 ± 4.0	n.a.	n.a.
27	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCCN3N=NC(CCN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)=O)C=C2)[C@@H]1O</chem>	29.3 ± 3.7	n.a.	n.a.
28	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCCCN3N=NC(CN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)=O)C=C2)[C@@H]1O</chem>	28.3 ± 8.1	n.a.	n.a.
29	<chem>O[C@H]1[C@@H](O)[C@@H](CO)O[C@@H](SC2=CC=C(NC(CCCCN3N=NC(CCN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)=O)C=C2)[C@@H]1O</chem>	26.2 ± 2.4	n.a.	n.a.
30	<chem>C[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CNS(C2=CC=C(CCN3N=NC(CN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)S2)(=O)=O)O1</chem>	n.a.	2.37 ± 1.2	2.24 ± 0.23
31	<chem>C[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CNS(C2=CC=C(CCN3N=NC(CCN(CC4)CCN4C5=C(F)C=C6C(N(C7CC7)C=C(C6=O)C(O)=O)=C5)=C3)S2)(=O)=O)O1</chem>	n.a.	2.53 ± 0.87	1.00 ± 0.06
5	<chem>O=C(O)[C@H]1[C@@H](OC(C)=O)[C@@H](COC(C)=O)O[C@@H](SC2=CC=C([N+](O-)=O)C=C2)[C@@H]1OC(C)=O)C</chem>	n.a.	n.a.	n.a.
6	<chem>NC(C=C1)=CC=C1S[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)O2</chem>	n.a.	n.a.	n.a.
7	<chem>O=C(CN=[N+]=[N-])NC(C=C1)=CC=C1S[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O2</chem>	n.a.	n.a.	n.a.
8	<chem>O=C(CCN=[N+]=[N-])NC(C=C1)=CC=C1S[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O2</chem>	n.a.	n.a.	n.a.
9	<chem>O=C(CCCN=[N+]=[N-])NC(C=C1)=CC=C1S[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O2</chem>	n.a.	n.a.	n.a.
10	<chem>O=C(CCCCN=[N+]=[N-])NC(C=C1)=CC=C1S[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O2</chem>	n.a.	n.a.	n.a.
16	<chem>BrCCC1=CC=C(S(=O)(Cl)=O)S1</chem>	n.a.	n.a.	n.a.

Table S3: key compounds and intermediates as smiles (n.a. = not applicable).

Figure S3: Purity of key compounds by HPLC-UV.














Table S4: Retention times measured by reversed-phase HPLC with a H₂O/MeCN system, using three gradients a-c: a. 5-55% B over 20 min; b. 5-30% B over 20 min; c. 2-25% B over 20 min. Eluent A: H₂O (0.1% formic acid), eluent B: MeCN (0.1% formic acid).

compound	target	m	n	gradient		
				a	b	c
				retention time t _R [min]		
22	LecA	0	1	9.0	12.5	15.7
23		1	1	9.0	12.9	15.7
24		0	2	8.6	11.7	14.9
25		1	2	8.9	12.3	15.5
26		0	3	9.1	12.7	15.9
27		1	3	9.2	12.9	16.1
28		0	4	9.5	13.5	16.7
29		1	4	9.6	13.7	17.0
30	LecB	0	-	10.0	14.4	17.7
31		1	-	10.2	14.7	18.0
3		-	-	7.0	8.5	11.6

Figure S4: representative chromatogram of conjugates **22 - 31** and ciprofloxacin (**3**) from slow gradient b (see table S4) HPLC runs for lipophilicity comparison. Top: full UV-chromatogram and gradient for eluent B, bottom: UV-chromatogram from t = 8.2 - 16.4 min.





References

1. Huang, X. Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. *J Biomol. Screen.* **2003**, *8*, 34-38.
2. Sommer, R.; Wagner, S.; Varrot, A.; Nycholat, C. M.; Khaledi, A.; Häussler, S.; Paulson, J. C.; Imberty, A.; Titz, A. The virulence factor LecB varies in clinical isolates: consequences for ligand binding and drug discovery. *Chem. Sci.* **2016**, *7*, 4990–5001.